RedHill Biopharma’s opaganib shows improved lung damage survival in publication

RedHill Biopharma announced a new publication of data from multiple experiments in the International Journal of Molecular Sciences showing that opaganib protects against radiation-induced lung inflammation and fibrosis in an in vivo mouse model of lung damage following exposure to ionizing radiation, demonstrating its potential use as a medical countermeasure against nuclear irradiation and in cancer radiotherapy. The opaganib group treated both during the initial and delayed phases of inflammation demonstrated a highly statistically significant improvement in survival at Day 180: 60% survival vs. 10% for controls. Thus, treating with opaganib during both initial and delayed phases of inflammation provided the greatest improvement in survival. Opaganib is being tested as a potential treatment for Acute Radiation Syndrome, following selection by the U.S government National Institutes of Health’s Radiation and Nuclear Countermeasures Program for its radiation medical countermeasures Product Development Program.